{"commentary":{"count":157,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":118,"youtube":27,"podcast":12},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04689828\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PSMAfore","nct_id":"NCT04689828","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=psmafore-nct04689828. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"PSMAfore","arms":[{"description":"Participants received 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT could be used.","label":"177Lu-PSMA-617","type":"EXPERIMENTAL"},{"description":"For participants randomized to the ARDT arm, abiraterone or enzalutamide was administered per the physician's orders. Best supportive care, including Androgen deprivation therapy (ADT) could be used.","label":"Androgen receptor-directed therapy (ARDT)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-09-10","type":"ESTIMATED"},"conditions":["Prostatic Neoplasms"],"enrollment":{"count":469,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"177Lu-PSMA-617","type":"DRUG"},{"name":"68Ga-PSMA-11","type":"DRUG"},{"name":"ARDT","type":"DRUG"}],"last_update":"2026-09-11","lead_sponsor":"Novartis Pharmaceuticals","official_title":"PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2022-10-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Radiographic Progression Free Survival (rPFS)","timeFrame":"median FU (randomization to event or censoring) 3.65 months (range 0-12.3)"}],"references":[{"citation":"Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D, Piulats JM, Flechon A, Wei XX, Mahammedi H, Roubaud G, Fleming M, Haas T, Ghebremariam S, Kreisl TN, Rajagopalan S, Sartor O, Morris MJ; PSMAfore Investigators. Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025 Nov;36(11):1319-1330. doi: 10.1016/j.annonc.2025.07.003. Epub 2025 Jul 17.","pmid":"40680993","type":"DERIVED"},{"citation":"Fizazi K, Morris MJ, Shore ND, Chi KN, Crosby M, de Bono JS, Herrmann K, Roubaud G, Nagarajah J, Fleming M, Lewis B, Nordquist L, Carnahan N, Ghebremariam S, Hertelendi M, Castellano D, Sartor O. Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial. Lancet Oncol. 2025 Jul;26(7):948-959. doi: 10.1016/S1470-2045(25)00189-5. Epub 2025 May 26.","pmid":"40441170","type":"DERIVED"},{"citation":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Flechon A, Wei XX, Mahammedi H, Roubaud G, Studentova H, Nagarajah J, Mellado B, Montesa-Pino A, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K; PSMAfore Investigators. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15.","pmid":"39293462","type":"DERIVED"}],"start_date":{"date":"2021-06-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04689828"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/psmafore-nct04689828"}